Abstract
Patients with first-episode schizophrenia (FES) are known to be notably sensitive for developing extrapyramidal adverse effects, but the relation of akathisia and suicidal ideation has rarely been studied. The current report is an ongoing analysis of an 8-week double-blind randomized controlled multicenter trial in 289 FES, comparing risperidone and haloperidol. Assessments were conducted weekly and included the Hillside Akathisia Scale and 21-item Hamilton Depression Rating Scale ratings. Suicidal ideation was significantly associated with clinician observed akathisia, depressed mood, younger age, and use of propranolol. The allocated treatment, anxiety, and nervousness had no influence. The present findings suggest a promoting effect of akathisia on suicidal ideation can not be ruled out in patients with FES.
Trial registration:
ClinicalTrials.gov NCT00159120.
Publication types
-
Comparative Study
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Age Factors
-
Akathisia, Drug-Induced / epidemiology
-
Akathisia, Drug-Induced / etiology
-
Antipsychotic Agents / adverse effects*
-
Antipsychotic Agents / therapeutic use
-
Depression / complications
-
Double-Blind Method
-
Female
-
Follow-Up Studies
-
Haloperidol / adverse effects*
-
Haloperidol / therapeutic use
-
Humans
-
Male
-
Propranolol / administration & dosage
-
Propranolol / adverse effects
-
Psychiatric Status Rating Scales
-
Psychomotor Agitation / epidemiology
-
Psychomotor Agitation / etiology
-
Risperidone / adverse effects*
-
Risperidone / therapeutic use
-
Schizophrenia / drug therapy*
-
Schizophrenia / physiopathology
-
Suicidal Ideation
-
Young Adult
Substances
-
Antipsychotic Agents
-
Propranolol
-
Haloperidol
-
Risperidone
Associated data
-
ClinicalTrials.gov/NCT00159120